Nate Wolf [Barron's]
Cidara Therapeutics, Inc. (CDTX)
Last cidara therapeutics, inc. earnings: 3/4 05:55 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cidara.com
Company Research
Source: Barrons
LATEST ARTICLES Wedbush Securities lifts its rating to Outperform from Neutral and says heavy spending next year will pay off in the long run. Shares of the stablecoin issuers are down almost 70% since June. Cidara Therapeutics is developing a drug designed to prevent the flu. The cuts are set to happen in the next week, with the company also planning to transition 200 stores to franchised locations, a report said. The cost of credit-default swaps for the company's debt continues to rise. Japanese competitor Kioxia reports a steep drop in profit compared with last year. Wedbush Securities reiterated an Outperform rating and a $925 price target for the stock. Mizuho Securities reiterated an Outperform rating and a $400 price target for the shares. The stablecoin issuer posted better-than-expected earnings and revenue but raised its forecast for operating costs. The chip maker's quarterly profit and revenue were higher than expected. The AI software firm discloses
Show less
Read more
Impact Snapshot
Event Time:
CDTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDTX alerts
High impacting Cidara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CDTX
News
- Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their RightsPR Newswire
- Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk PopulationsGlobeNewswire
- SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTXPR Newswire
- Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025 [Forbes]Forbes
- Cidara Therapeutics (NASDAQ:CDTX) had its "neutral" rating reaffirmed by analysts at Guggenheim.MarketBeat
CDTX
Earnings
- 11/6/25 - Miss
CDTX
Sec Filings
- 12/5/25 - Form SC
- 12/5/25 - Form SC
- 11/17/25 - Form SCHEDULE
- CDTX's page on the SEC website